Clinical Trial Update: Safety and Immunogenicity of CJ-50300 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and immune response of CJ-50300 for smallpox has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• CJ-50300

Snippet

Sponsor: Seoul National University Hospital | Conditions: Smallpox | Phase 1 | Status: COMPLETED